CJC-1295

Amino Acid Sequence:

YADAXFXQSYRKVLAQLSARKLLQDXLSR

Chemical Formula:

C₁₅₂H₂₅₂N₄₄O₄₂

CAS Registry Number:

863288‑34‑0

• Enhanced GH and IGF‑1 secretion

• Body‑composition improvement

• Metabolic regulation (lipid oxidation, glucose handling)

• Cellular repair & recovery

• Sleep quality and circadian rhythm support

• Healthy aging & vitality research

• Adjunctive interest in muscle‑wasting conditions

GHRH Analog Activity

• Binds to GHRH receptors in the pituitary

• Stimulates physiologic GH pulsatile release

• Increases downstream IGF‑1 production

Drug Affinity Complex (DAC) Modification

• Enables albumin binding

• Extends half‑life from minutes to ~1 week

• Supports sustained GH/IGF‑1 elevation

Metabolic & Cellular Effects

• Enhances lipid oxidation and glucose handling

• Supports muscle protein synthesis

• Promotes cellular repair and recovery

• Modulates immune and inflammatory pathways

Circadian & Neurological Influence

• May support sleep quality and circadian rhythm regulation

CJC‑1295 is an experimental research peptide and is not FDA‑approved, with most data coming from preclinical and early human studies. Even so, it has gained significant real‑world interest due to widespread anecdotal reports describing benefits in recovery, sleep, metabolism, and overall vitality. While more large‑scale research is needed, this combination of promising early findings and substantial user‑reported experience continues to drive scientific and community curiosity around GH‑modulating peptides.

1. Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., & Castaigne, J. P. (2006). Prolonged stimulation of growth hormone (GH) and insulin‑like growth factor‑1 (IGF‑1) secretion by CJC‑1295, a long‑acting GHRH analog. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805.

2. Ionescu, M., Frohman, L. A., & Castaigne, J. P. (2005). Pharmacokinetics and pharmacodynamics of CJC‑1295, a long‑acting growth hormone–releasing hormone analog. Growth Hormone & IGF Research, 15(5), 313–323.

3. Castaigne, J. P., & Teichman, S. L. (2007). Long‑acting GHRH analogs and their role in GH modulation. Endocrine Reviews, 28(6), 758–773.

4. Frohman, L. A., & Kineman, R. D. (2002). Regulation of growth hormone secretion by GHRH analogs and somatostatin. Endocrine Reviews, 23(6), 782–802.

5. Chapman, I. M. (2013). The role of GH and IGF‑1 in metabolism and aging: implications for GHRH analogs. Clinical Interventions in Aging, 8, 133–145.

6. Veldhuis, J. D., & Bowers, C. Y. (2010). Physiologic GH pulsatility and therapeutic modulation. Nature Reviews Endocrinology, 6(9), 520–528.

7. Liu, H., Bravata, D. M., Olkin, I., et al. (2007). Systematic review of GH and IGF‑1 effects on body composition and metabolism. Annals of Internal Medicine, 146(9), 642–654.

CURRENT BATCH LOT NUMBER: CND102026-04-07

CERTIFICATE OF ANALYSIS – TGMPURE CJC-1295 10 MG (CND102026-04-07)